HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Precision Oncology for Metastatic Prostate Cancer: Translation into Practice.

Abstract
While the principles of precision medicine have been readily embraced by all stakeholders, multiple conceptional and structural challenges hinder its broad implementation in clinical practice. PROfound provides the highest level of evidence for the use of a poly(adenosine diphosphate-ribose) polymerase inhibitor in prostate cancer so far. It is an undoubtedly positive trial, but it also clearly shows the complexity of precision oncology for prostate cancer and the challenges of translating genomics into treatment for metastatic castration-resistant disease.
AuthorsMaria De Santis, Nicolas Mottet, Philip Cornford, Silke Gillessen, EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel
JournalEuropean urology (Eur Urol) Vol. 78 Issue 6 Pg. 771-774 (12 2020) ISSN: 1873-7560 [Electronic] Switzerland
PMID32863055 (Publication Type: Editorial)
CopyrightCopyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Topics
  • Humans
  • Male
  • Medical Oncology (methods)
  • Precision Medicine
  • Prostatic Neoplasms (drug therapy)
  • Translational Research, Biomedical

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: